PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · News & media

New data released on weight loss drug retatrutide

News & media2:55May 2026

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

This segment features the show's chief medical correspondent, who discusses retatrutide, an experimental weight loss medication still in clinical trials. According to the video, it is a once-a-week injection that targets three hormones: GLP-1, GIP and glucagon. She contrasts that with Zepbound, which she says targets two hormones, and Wegovy, which she says targets one. She explains that it works much like the others by slowing digestion, lowering appetite, aiding fat breakdown and improving insulin sensitivity.

Published by Good Morning America on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

The correspondent shares figures from the latest trials. She says people on the highest dose for 80 weeks lost about 70 lbs, roughly 28% of their body weight, while those on a 4 mg dose lost about 47 lbs, or about 19%. She says 45% of participants lost more than 30% of their body weight, and 65% moved from the obese category to below it. In a small subset with a BMI over 35 followed for 100 weeks, she says the loss was 85 lbs.

She says the drug could give another option to patients who could not tolerate Zepbound or Wegovy or who plateaued on them, and to people with severe obesity. She adds that the data suggest people lose more fat than muscle. On timing, she says the drug is still experimental, with an FDA submission expected in 2027 or 2028, and that it is being studied for conditions beyond obesity and diabetes. She warns that any retatrutide being advertised now is not the real drug.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:31 The correspondent says retatrutide is a weekly injection targeting three hormones (GLP-1, GIP and glucagon), compared with two for Zepbound and one for Wegovy.
  2. 1:01 She reports that people on the highest dose for 80 weeks lost about 70 lbs, or about 28% of body weight, and those on 4 mg lost about 47 lbs, or about 19%.
  3. 1:32 She says a small subset with a BMI over 35, followed for 100 weeks, lost 85 lbs.
  4. 1:42 She says it offers another option for patients who could not tolerate or plateaued on Zepbound or Wegovy, and for people with severe obesity.
  5. 2:02 She says the data show people lose more fat than muscle on this drug.
  6. 2:20 She says it is still experimental, with an FDA submission expected in 2027 or 2028, and warns that products advertised now as retatrutide are not the real drug.

Key moments

Tap one to play from there.

  1. 0:00 Introduction
  2. 1:05 Dose change
  3. 2:13 Wrapping up

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy, Zepbound and retatrutide

Questions this video answers

How much weight did people lose on retatrutide in trials?

According to the video, people on the highest dose for 80 weeks lost about 70 lbs, around 28% of their body weight. Those on a 4 mg dose lost about 47 lbs, or about 19%. She also says a small subset with a BMI over 35 lost 85 lbs over 100 weeks.

How is retatrutide different from Zepbound and Wegovy?

The doctor explains that retatrutide targets three hormones: GLP-1, GIP and glucagon. She says Zepbound targets two hormones and Wegovy targets one. It is a once-a-week injection like the others.

When will retatrutide be approved by the FDA?

She says it is still experimental and in trials. The makers expect to bring it to the FDA for approval in 2027 or 2028.

Is retatrutide being sold online the real drug?

According to the video, no. She says that if you see the drug advertised now, it is not the real thing, and she advises people to be careful.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Retatrutide: FDA status, trial results and when it could be approved

    Retatrutide is not FDA-approved: Eli Lilly plans to submit it in Q1 2027, and FDA says it cannot be compounded. The weekly triple agonist (GIP, GLP-1 and glucagon) produced 28.3% weight loss at 80 weeks in TRIUMPH-1 on Lilly's efficacy measure (25.0% counting everyone randomized), and in October 2026 it beat Ozempic 2 mg head to head. Online "research" vials are illegal. Tirzepatide is the closest legal option, compounded from $69 a month on our board.

  • GLP-1 vs GLP-2 vs GLP-3: what the names mean, and which ones you can actually buy

    GLP-1 drugs such as semaglutide act on one receptor. "GLP-2" is used online for tirzepatide (Zepbound, Mounjaro), which acts on two, GIP and GLP-1, and "GLP-3" for retatrutide, which adds the glucagon receptor. Neither nickname is the real name: GLP-2 is a separate gut hormone whose drug, Gattex, treats short bowel syndrome. Retatrutide produced 28.3% mean weight loss at 80 weeks in its phase 3 trial but is not FDA-approved; Lilly plans to file in Q1 2027. Tirzepatide is the strongest option you can buy today.

  • What is Zepbound? Tirzepatide explained: what it treats, how it works, and what it costs

    Zepbound is Eli Lilly's brand of tirzepatide, a once-weekly injection that acts on two hormone receptors, GIP and GLP-1. The FDA label approves it, with diet and exercise, for weight reduction in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-5 trial it produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide. Lilly sells it self-pay from $299 a month.

Find more like it

Dose changeWeigh-in and resultsThe trials

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV